Certain Heavy Machinery and Components Thereof — Representing Caterpillar in a global dispute against Doosan Bobcat North America Inc. (“Bobcat”) involving patent infringement allegations over skid-steer loaders, compact track loaders, excavators, wheel loaders, dozers and components.
Aetna Inc. v. Gilead Sciences, Inc., et al. — Representing Gilead Sciences, Inc. and two of its subsidiaries in antitrust litigation alleging an anti-competitive reverse payment arising out of a patent litigation settlement concerning the development and sale of certain HIV treatments.
Astellas Pharma Inc. et al v. Ascent Pharmaceuticals, Inc. et al. — Representing Astellas in a Hatch-Waxman litigation filed against Ascent Pharmaceuticals and MSN Laboratories related to Astellas’ Myrbetriq®, used to treat overactive bladder.
Astellas Pharma Inc., et al. v. Lupin Limited, et al. — Astellas brought Kirkland in after the trial court invalidated the company’s patent in a bench trial and two defendants, Zydus and Lupin, launched their generic products. After jury selection in a February 2026 trial, the case settled with Astellas receiving several hundred million dollars and ongoing payments for further product sales.
Amgen Inc. et al v. Samsung Bioepis Co. Ltd., et al. — Representing Samsung Bioepis in a BPCIA patent infringement action brought by Amgen regarding Samsung Bioepis’s proposed biosimilar versions of Amgen’s Prolia® and XGEVA® (denosumab), prescribed as bone-strengthening treatments. Samsung Bioepis filed counterclaims of noninfringement and invalidity of the 34 asserted patents.
Pacira v. Research Development Foundation — Represented Pacira in a patent licensing dispute involving EXPAREL®, a first-of-its-kind, nonopioid, local anesthetic for postsurgical pain. In 2025, the court entered judgment in favor of Pacira. As a result, Pacira is positioned to recover four years of royalties paid under protest, and can produce EXPAREL® royalty-free going forward.
